Open Beta
TREN
MetriLume
TREN

US marketsCUE

SEC-sourced researchBeta

CUE

Cue Biopharma, Inc.

Company comparison ↗

Data passport

CIK
0001645460
Exchange
Nasdaq
Business activity
— · SIC 2834
Financial inputs
6/6
Filing date
Sep 21, 2026
SEC registry record
Operating company
Last updated: SEC company ticker catalog ↗SEC Financial Statement Data Sets ↗SEC investment company series and class registry ↗

Annual financial history

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table. Exact amounts and source periods: December 2024: 9,287,000.0000 USD; December 2025: 27,466,000.0000 USD27.5M USD0 USD0December 2024December 2025
CUE · Exact amounts and source periods · USD
Period endRevenueFiling date
December 20249,287,000.0000Mar 16, 2026
December 202527,466,000.0000Mar 16, 2026

Annual periods · USD

Period endRevenueNet incomeOperating cash flowTotal assetsTotal liabilitiesFiling date
December 202527,466,000.0000-26,602,000.0000-21,687,000.000042,212,000.000015,780,000.0000Mar 16, 2026
December 20249,287,000.0000-40,674,000.0000-36,329,000.000032,191,000.000014,692,000.0000Mar 16, 2026

Financial inputs behind the calculation

Financial inputsUSDPeriod endFiling dateForm
RevenueRevenueFromContractWithCustomerExcludingAssessedTax$27.47MDecember 2025Mar 16, 202610-K
Previous period revenueRevenueFromContractWithCustomerExcludingAssessedTax$9.29MDecember 2024Mar 16, 202610-K
Net incomeNetIncomeLoss-$26.6MDecember 2025Mar 16, 202610-K
Operating cash flowNetCashProvidedByUsedInOperatingActivities-$21.69MDecember 2025Mar 16, 202610-K
Total assetsAssets$42.21MDecember 2025Mar 16, 202610-K
Total liabilitiesLiabilities$15.78MDecember 2025Mar 16, 202610-K

New filings

Explore methodology ↗